| Literature DB >> 29204449 |
Yunlu Gao1, Xuemei Yi1, Yangfeng Ding1.
Abstract
RNA-seq has enabled in-depth analysis of the pathogenesis of psoriasis on the transcriptomic level, and many biomarkers have been discovered to be related to the immune response, lipid metabolism, and keratinocyte proliferation. However, few studies have combined analysis from various datasets. In this study, we integrated different psoriasis RNA-seq datasets to reveal the pathogenesis of psoriasis through the analysis of differentially expressed genes (DEGs), pathway analysis, and functional annotation. The revealed biomarkers were further validated through proliferation phenotypes. The results showed that DEGs were functionally related to lipid metabolism and keratinocyte differentiation dysregulation. The results also showed new biomarkers, such as AKR1B10 and PLA2G gene families, as well as pathways that include the PPAR signaling pathway, cytokine-cytokine receptor interaction, alpha-linoleic acid metabolism, and glycosphingolipid biosynthesis. Using siRNA knockdown assays, we further validated the role that the AKR1B10 gene plays in proliferation. Our study demonstrated not only the dysfunction of the AKR1B10 gene in lipid metabolizing but also its important role in the overproliferation and migration of keratinocyte, which provided evidence for further therapeutic uses for psoriasis.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29204449 PMCID: PMC5674492 DOI: 10.1155/2017/8717369
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Quantitative PCR primers sequence.
| qPCR primer | Forward (5′ → 3′) | Reverse (5′ → 3′) | Product length |
|---|---|---|---|
| AKR1B10 | CCCAGGTTCTGATCCGTTT | GCAACACGTTACAGGCCC | 171 bp |
| GAPDH | GAGTCCACTGGCGTCTTCAC | TGCTGATGATCTTGAGGCTGTT | 141 bp |
The synthetic siRNA sequence.
| siRNA | Forward sequence (5′ → 3′) | Reverse sequence (5′ → 3′) |
|---|---|---|
| siRNA-1121 | CACGCAUUGUUGAGAACAUTT | AUGUUCUCAACAAUGCGUGTT |
| siRNA-1239 | GGAAGACUAUCCCUUCAAUTT | AUUGAAGGGAUAGUCUUCCTT |
| siRNA-452 | GUGCCUAUGUCUAUCAGAATT | UUCUGAUAGACAUAGGCACTT |
Figure 1Principal component analysis shows that the psoriasis samples were clustered together and separated from normal samples. The nonlesional samples were clustered together with the samples of healthy individual.
Figure 2This Venn diagram shows the 696 genes identified as DEGs in both datasets.
Pathway enrichment analysis of 696 common DEGs.
| Term | Count | % |
| Genes |
|---|---|---|---|---|
| hsa03320: PPAR signaling pathway | 12 | 1.7 | 1.10 | ACOX2, LPL, PPARD, ACSL1, HMGCS2, PPARG, FADS2, FABP7, ACADL, SLC27A2, MMP1, FABP5 |
| hsa04060: cytokine-cytokine receptor interaction | 25 | 3.6 | 1.94 | CXCL1, TNFRSF21, IL19, IL21R, CXCL9, CXCR2, CXCR3, KIT, IL7R, CCL20, CXCR4, IL4R, IL1B, IL6, IL18RAP, IL2RA, IL8, LIFR, EDAR, CCL18, IL20, CCR7, CCR5, CXCL13, EDA |
| hsa00592: alpha-linolenic acid metabolism | 6 | 0.8 | 6.60 | JMJD7-PLA2G4B, PLA2G2A, FADS2, PLA2G3, PLA2G4B, PLA2G4E, PLA2G2F |
| hsa00601: glycosphingolipid biosynthesis | 6 | 0.8 | 3.22 | FUT9, B3GALT5, FUT3, B3GNT3, FUT1, FUT2 |
| hsa00591: linoleic acid metabolism | 6 | 0.8 | 5.39 | JMJD7-PLA2G4B, AKR1B15, AKR1B10, PLA2G2A, PLA2G3, PLA2G4B, PLA2G4E, PLA2G2F |
| hsa04640: hematopoietic cell lineage | 10 | 1.4 | 9.08 | IL6, IL2RA, CD3G, CD3D, CD3E, IL4R, CD2, IL1B, KIT, IL7R |
| hsa04062: chemokine signaling pathway | 16 | 2.3 | 1.08 | CXCL1, ITK, LYN, IL8, CXCL9, CXCR2, CXCR3, STAT1, CCL18, CCR7, PLCB4, CCR5, CCL20, CXCR4, CXCL13, JAK3 |
| hsa00565: ether lipid metabolism | 6 | 0.8 | 1.41 | JMJD7-PLA2G4B, PLA2G2A, PLA2G3, PLA2G4B, CHPT1, PLA2G4E, PLA2G2F |
| hsa05340: primary immunodeficiency | 6 | 0.8 | 1.41 | CD3D, CD3E, ICOS, LCK, JAK3, IL7R |
| hsa00603: glycosphingolipid biosynthesis | 4 | 0.5 | 1.85 | FUT9, B3GALT5, FUT1, FUT2 |
| hsa00564: glycerophospholipid metabolism | 8 | 1.1 | 2.22 | GPD1, JMJD7-PLA2G4B, PLA2G2A, PLA2G3, PNPLA3, PLA2G4B, CHPT1, PLA2G4E, PLA2G2F |
| hsa04730: long-term depression | 8 | 1.1 | 2.39 | JMJD7-PLA2G4B, PLCB4, GRIA2, LYN, PLA2G2A, PLA2G3, PLA2G4B, PLA2G4E, PLA2G2F |
| hsa00590: arachidonic acid metabolism | 7 | 1.0 | 2.80 | JMJD7-PLA2G4B, ALOX15B, PLA2G2A, ALOX12B, PLA2G3, PLA2G4B, PLA2G4E, PLA2G2F |
| hsa04514: cell adhesion molecules (CAMs) | 11 | 1.6 | 4.78 | CLDN16, CLDN8, CD80, NRXN3, SELL, ICOS, CD274, CD2, CTLA4, CDH2, CD226 |
GO annotation results of 696 common DEGs.
| Term | Count | % |
| Genes |
|---|---|---|---|---|
| GO:0031424~keratinization | 15 | 4.7 | 3.15 | HRNR, LCE3A, LCE3D, SPRR2G, SPRR2F, LCE1B, SPRR2E, SPRR2C, SPRR2D, SPRR1B, SPRR2A, SPRR2B, CNFN, TGM1, TGM3, LCE3E |
| GO:0007398~ectoderm development | 25 | 7.9 | 6.38 | HRNR, KRT6A, KRT6B, LCE3A, S100A7, CRABP2, LCE3D, SPRR2G, LCE1B, SPRR2F, SPRR2E, SPRR2C, SPRR2D, SPRR2A, SPRR2B, TGM1, ALOX12B, TGM3, GRHL3, EDAR, KRT16, SPRR1B, CNFN, LCE3E, EDA, FABP5 |
| GO:0030216~keratinocyte differentiation | 16 | 5.0 | 1.35 | HRNR, LCE3A, S100A7, LCE3D, SPRR2G, SPRR2F, LCE1B, SPRR2E, SPRR2C, SPRR2D, SPRR1B, SPRR2A, SPRR2B, CNFN, TGM1, TGM3, LCE3E |
| GO:0009913~epidermal cell differentiation | 16 | 5.0 | 5.24 | HRNR, LCE3A, S100A7, LCE3D, SPRR2G, SPRR2F, LCE1B, SPRR2E, SPRR2C, SPRR2D, SPRR1B, SPRR2A, SPRR2B, CNFN, TGM1, TGM3, LCE3E |
| GO:0006955~immune response | 44 | 14.0 | 6.22 | CXCL1, KYNU, S100A7, IL19, OAS3, RSAD2, OAS1, OAS2, DEFB4A, IL7R, PNP, NOD2, CCL20, RAET1G, HRH2, IL4R, BCL3, VNN1, IL1B, LTF, CCBP2, NOS2, FCGR3A, GBP6, IL18RAP, GBP5, LYN, IL8, CTLA4, CD300E, SLAMF7, AIM2, OASL, CCR7, APOL1, CST7, CXCL13, CD274, SERPINB4, CLEC7A, EDA, IFI6, PTAFR, GBP1 |
| GO:0008544~epidermis development | 23 | 7.3 | 7.26 | HRNR, LCE3A, S100A7, LCE3D, CRABP2, SPRR2G, GRHL3, SPRR2F, LCE1B, SPRR2E, EDAR, SPRR2C, SPRR2D, KRT16, SPRR1B, SPRR2A, TGM1, SPRR2B, CNFN, ALOX12B, TGM3, LCE3E, EDA, FABP5 |
| GO:0030855~epithelial cell differentiation | 18 | 5.7 | 1.06 | HRNR, LCE3A, S100A7, LCE3D, SPRR2G, SPRR2F, LCE1B, SPRR2E, RHCG, SPRR2C, SPRR2D, SPRR1B, SPRR2A, UPK1B, SPRR2B, CNFN, TGM1, TGM3, LCE3E |
| GO:0060429~epithelium development | 19 | 6.0 | 3.98 | HRNR, LCE3A, S100A7, LCE3D, SPRR2G, SPRR2F, LCE1B, SPRR2E, RHCG, SPRR2C, SPRR2D, FREM2, SPRR1B, SPRR2A, UPK1B, SPRR2B, CNFN, TGM1, TGM3, LCE3E |
| GO:0006952~defense response | 31 | 9.8 | 2.58 | CXCL1, KYNU, S100A8, S100A7, S100A9, RSAD2, CXCR2, DEFB4A, NOD2, CCL20, VNN1, IL1B, LTF, BCL3, SERPINA1, NOS2, MX1, IRAK2, IL18RAP, LYN, IL8, LYZ, SLAMF7, IDO1, S100A12, CCR7, APOL1, CXCL13, IRF7, CLEC7A, PTAFR |
| GO:0002684~positive regulation of immune system process | 17 | 5.4 | 1.47 | IRAK2, LYN, CD247, PTPN22, IDO1, IL7R, PNP, PRKCQ, NOD2, CD80, IL4R, CD2, IL1B, VNN1, CLEC7A, NOS2, CD226 |
Genes related to lipid metabolism were dysregulated in both datasets.
| GSE54456 | GSE66511 | |||
|---|---|---|---|---|
| Fold change | FDR | Fold change | FDR | |
| PLA2G4D | 20.52 | 2.93 | 6.66 | 1.64 |
| PLA2G4E | 4.69 | 4.87 | 3.20 | 1.85 |
| PLA2G2F | 4.25 | 5.65 | 2.90 | 1.71 |
| PLA2G3 | 4.19 | 2.10 | 2.86 | 8.65 |
| PLA2G4B | 3.70 | 1.26 | 2.72 | 1.30 |
| JMJD7-PLA2G4B | 2.43 | 1.54 | 2.65 | 4.29 |
| PLA2G2A | 2.12 | 1.28 | 6.11 | 1.29 |
|
|
| 1.37 |
| 7.42 |
| AKR1B15 | 60.88 | 2.03 | 2.80 | 1.31 |
Figure 3Coexpression network of lipid metabolism genes. Each point represents a gene, and lines indicate the interaction between two genes.
Figure 4AKR1B10 expression after being transfected with HilyMax (Vector), siRNA-1121, siRNA-1239, and siRNA-452 in HACAT cells. The knockdown groups and the NC group (control) had statistically significance differences (p < 0.001). ∗∗∗ refers to p < 0.001.
Figure 5The proliferation of HACAT cells was evaluated with the CCK-8 assay. The results showed significant downregulation of cell proliferation between the knockdown groups and NC group (p < 0.01), and there is no significant difference between the NC and Vector groups. ∗∗ refers to p < 0.01.
Figure 6Scratch wound-healing assay. The migration ability of HACAT cells is inhibited by siRNA-452 (p < 0.01) and siRNA-1121 (p < 0.01) interference compared to the NC group. ∗∗ refers to p < 0.01.